Avalign And Subsidiary Instrumed To Pay $9.5M In Uncleared Device Settlement
Executive Summary
Avalign Technologies is paying $9.5m to settle fraud charges. The company and its Instrumed International subsidiary sold unapproved devices that they falsely claimed held pre-amendment status.
You may also be interested in...
FCA 2019: Key Issues Include DOJ Dismissal, Statute Of Limitations
Court rulings related to the False Claims Act (FCA) this year focused on whistleblower rules and further clarifying the theory of liability, given in the Supreme Court’s 2016 Escobar decision, Gibson Dunn health-care attorneys say.
‘Core Pillars’ Of Safety And Innovation Take Center Stage In FDA Reports
The US FDA has issued a pair of reports focused on device safety and innovation. The reports describe recent steps the agency has taken to improve in the two areas, and what it plans to do next.
Interview: Theradaptive To Enter Clinical Trial For Spinal Fusion Implant
Theradaptive, which makes a device-biologic combination product to help speed bone healing, recently got authorization to start human trials from the US FDA. Medtech Insight spoke to CEO Luis Alvarez about the company’s past, present and future.